OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
 
Home Antibody All anti-EGFR antibodies

Anti-EGFR Antibody

div

Specifications Citations (0) Related Products Product Documents
SKU Description Amount Price Availability*  
TA319215
  • Rabbit polyclonal anti-EGFR antibody
  • Free Sample of Positive Control: HEK293T cell transient overexpression lysate (LC404515) , 20ug Explanation
250ul $325 3-7 Days

Buy any antibody of 100ul or more, get a free package of 3 loading control antibody samples. View Details Add to Shopping Cart

spacer
WB(2)
IHC(1)

OriGene Data

ImmunogenThis whole rabbit serum was prepared by repeated immunizations with a peptide synthesized using conventional technology.  The sequence of the epitope maps to a region near the carboxy terminus which is identical in human, mouse and rat EGFR.
Clone Name IsotypeIgG
Species Reactivityhuman, mouse, rat Concentration85 mg/mL
Guaranteed Application *WB, IHC Suggested DilutionsELISA: 1:10,000 - 1:50,000, WB: 1:1,000 - 1:10,000, IHC: 2.5 ug/mL, IP: 10 ul
BufferNone
Note EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial to maintaining a normal balance in cell growth and development.  Growth factor receptors are involved not only in promoting the proliferation of normal cells but also in the aberrant growth of many types of human tumors.  For example, the epidermal growth factor receptor (EGFR) is mutated and/or over-expressed in many common solid human squamous cell carcinomas including breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. Over-expression of the EGFR gene occurs in carcinomas with and without gene amplification. EGFR and ErbB-2 are particularly important in breast cancer because increased production or activation has been associated with poor prognosis. EGFR belongs to a family of growth factor receptors, which also includes ErbB-2/HER-2/neu, ErbB-3/HER-3/neu and ErbB-4/HER-4/neu. EGFR can heterodimerize with each of the members of this family.

* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.

Western blot using anti-EGFR antibody shows detection of a band at ~170 kDa corresponding to human EGFR present in unstimulated (lane 1) and EGF (50 ng/ml for 15 min) stimulated (lane 2) A431 whole cell lysates (arrowhead). Approximately 30 µg of lysate was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. After blocking, the membrane was probed with the primary antibody diluted to 1:1,000. Reaction occurred overnight at 4° C followed by washes and reaction with a 1:10,000 dilution of IRDye® 800 conjugated Gt-a-Rabbit IgG (H&L) MX10 (611-132-122) for 45 min at room temperature (800 nm channel, green). Molecular weight estimation was made by comparison to prestained MW markers in lane M (700 nm channel, red). IRDye® 800 fluorescence image was captured using the Odyssey® Infrared Imaging System developed by LI-COR. IRDye is a trademark of LI-COR, Inc. Other detection systems will yield similar results.
spacer
Combined immunoprecipitation and western blot using anti-EGFR antibody. Lysates were prepared from GN4 rat liver epithelial cells both with (+) EGF treatment for 15' at 100 ng/ml and without (-) the addition of EGF. The combination of immunoprecipitation and western blotting was performed using the anti-EGFR antibody for immunoprecipitation (10 µL) followed by western blot detection using an anti-phosphotyrosine antibody (Panel A). This was repeated in reverse order using a 1:2000 dilution of anti-EGFR for western blot (Panel B). Visualization occurred using an ECL system. Film exposure was approximately 1’. Other detection systems will yield similar results.
spacer
Combined immunoprecipitation and western blot using anti-EGFR antibody. Lysates were prepared from GN4 rat liver epithelial cells both with (+) EGF treatment for 15' at 100 ng/ml and without (-) the addition of EGF. The combination of immunoprecipitation and western blotting was performed using the anti-EGFR antibody for immunoprecipitation (10 µl) followed by western blot detection using an anti-phosphotyrosine antibody (Panel A). This was repeated in reverse order using a 1:2000 dilution of anti-EGFR for western blot (Panel B). Visualization occurred using an ECL system. Film exposure was approximately 1’. Other detection systems will yield similar results.
spacer

 

spacer
Inc 5000 Healthcare Company
All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title